VERAXA Biotech (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC(R) T-cell engager ...

ATUM, a leading US-based contract research organization, selected to support stable clonal cell line generation to advance VERAXA’s lead BiTAC-TCE program toward IND/CTA-enabling activities ...

Streamline cell line transfer with flexible process design, data-driven strategies, and real-world insights to reduce risk ...

For NK cell expansion, engineered ARH-77 cells may end the current bottleneck by increasing yield by more than 100,000-fold in one month.

Successfully producing large quantities of biotherapeutics, including monoclonal antibodies and recombinant protein products, depends on robust and reliable cell line development (CLD). Issues that ...

Combining cutting-edge proprietary technologies and enhanced manufacturing, TG4070 is positioned as a novel vaccine relevant to multiple tumor ...

To date, more than 100 clinical trials with human pluripotent stem cell (hPSC)-derived products have been initiated worldwide and an increasing number of potential hPSC-derived clinical products have ...

WHO-origin Master and Working Cell Banks provide vaccine developers with a ready-to-use Vero cell substrate for licensing, purchase, and integrated CDMO programs ...

The most complex engineering of human cell lines ever has been achieved by scientists, revealing that our genomes are more resilient to significant structural changes than was previously thought.

WUHAN, HUBEI PROVINCE, CHINA, February 15, 2026 /EINPresswire.com/ — In the complex landscape of life science research, selecting the right cellular model is a ...